- Conditions
- Bilingualism, Late Talkers, Network Science, Vocabulary Acquisition
- Interventions
- Large Semantic Category Condition, Small Semantic Category Condition
- Behavioral
- Lead sponsor
- Boston University Charles River Campus
- Other
- Eligibility
- 24 Months to 30 Months
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Location Directory
Clinical trials in Boston, Massachusetts
This page shows live ClinicalTrials.gov search results for Boston, Massachusetts, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
9275
Shown on this page
12
Local exact-city summaries
9275
Based on exact city/state matches in the local index.
Local exact-city recruiting
1894
Live official results below use the broader ClinicalTrials.gov location search.
Showing 1–12 of 9,275 matching trials in Boston, MA.
Indexed local directory records.
Top conditions in local exact-city summaries
Top sponsors in local exact-city summaries
Top therapies in local exact-city summaries
Indexed official records
Open in full search- Conditions
- Intracerebral Haemorrhage, Ischemic Stroke, Stroke, TIA (Transient Ischemic Attack)
- Interventions
- Savvy Medication Adherence Intervention
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- End Stage Kidney Disease (ESRD)
- Interventions
- Standard of Care (AVF creation), The Amplifi System is a temporary extracorporeal blood pump designed to deliver controlled flow through a peripheral vein for 24-72 hours prior to AVF creation.
- Procedure · Device
- Lead sponsor
- Amplifi Vascular, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
- Interventions
- Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 187
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 149 more
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- COYA 302, Placebo
- Drug
- Lead sponsor
- Coya Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more
- Conditions
- Epilepsy, Epilepsy (Treatment Refractory)
- Interventions
- Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system)
- Device
- Lead sponsor
- Epiminder America, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Irvine, California • Palo Alto, California + 13 more
- Conditions
- Relapsed/Refractory Primary Central Nervous System Lymphoma
- Interventions
- Rituximab, Temozolomide, Tirabrutinib
- Drug
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Fullerton, California • New Haven, Connecticut + 5 more
- Conditions
- Menopause-related Hot Flashes
- Interventions
- elinzanetant - reference formulation, placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Mirdametinib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 6
- States / cities
- Duarte, California • Irvine, California • Sacramento, California + 3 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Miami, Florida • Cordele, Georgia + 6 more
- Conditions
- AIDS, Adherence, Treatment, Depression, HIV
- Interventions
- Core Implementation Strategies, Enhanced Implementation Strategies
- Other
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Miami, Florida • Boston, Massachusetts
- Conditions
- Castration-resistant Prostate Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
- Interventions
- DCC-2812
- Drug
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • Nashville, Tennessee + 2 more